Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23306703 | 0.89 | ALDH1A1 (0.36) | ALDH1A1TSHRHSD17B10TDP1LMNA | |
| SCHEMBL7248068 | 0.86 | ALDH1A1 (0.41) | ALDH1A1TSHRTDP1MEN1KMT2A | |
| SCHEMBL27747608 | 0.77 | ALDH1A1 (0.41) | ALDH1A1TSHRHSD17B10TDP1 | |
| SCHEMBL27583396 | 0.76 | — | — | |
| SCHEMBL103304 | 0.75 | OPRK1 (0.42) | ALDH1A1TSHRHSD17B10TDP1LMNA | |
| SCHEMBL346040 | 0.73 | NOS3 (0.36) | ALDH1A1TSHRCA12CA1CA2 | |
| SCHEMBL3414095 | 0.73 | DNM1 (0.40) | ALDH1A1TSHRHSD17B10TDP1LMNA | |
| SCHEMBL28238471 | 0.73 | HCAR2 (0.35) | — | |
| SCHEMBL12755125 | 0.73 | PRKCA (0.31) | — | |
| SCHEMBL196772 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 441 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312606-A1 | MCL-1 INHIBITOR FORMULATIONS | AMGEN INC. (US) | 2023-10-05 | — | — | US | claimed |
| EP-4203922-A1 | MCL-1 INHIBITOR FORMULATIONS | Amgen Inc. (US) | 2023-07-05 | — | — | EP | claimed |
| CN-116115581-A | Ketorolac tromethamine biphasic controlled release tablet and preparation method thereof | 中国人民解放军中部战区总医院 | 2023-05-16 | — | — | CN | claimed |
| US-20220000788-A1 | METHOD FOR DRY POWDER COATING CAPSULES | NINGBO WESTON POWDER PHARMA COATINGS CO., LTD. (CN) | 2022-01-06 | — | — | US | claimed |
| EP-3821882-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen Inc. (US) | 2021-05-19 | — | — | EP | claimed |
| US-20200222330-A1 | METHOD FOR DRY POWDER COATING CAPSULES | POWDER PHARMA COATING INC. (CA) | 2020-07-16 | — | — | US | claimed |
| US-20190099378-A1 | METHOD FOR DRY POWDER COATING CAPSULES | NINGBO WESTON POWDER PHARMA COATINGS CO., LTD. (CN) | 2019-04-04 | — | — | US | claimed |
| US-20190099377-A1 | METHOD FOR DRY POWDER COATING OSMOTIC DRUG DELIVERY SYSTEM | NINGBO WESTON POWDER PHARMA COATINGS CO., LTD. (CN) | 2019-04-04 | — | — | US | claimed |
| CN-109200028-A | A kind of dry coating process preparing drug osmotic pump preparation | 宁波西敦医药包衣科技有限公司 | 2019-01-15 | — | — | CN | claimed |
| WO-2013168177-A2 | OSMOTICALLY CONTROLLED DRUG DELIVERY SYSTEMS | RUBICON RESEARCH PRIVATE LIMITED (IN) | 2013-11-14 | — | — | WO | claimed |
| EP-1502591-A2 | Controlled-release formulations coated with aqueous dispersions of ethylcellulose | EURO-CELTIQUE S.A. (LU) | 2005-02-02 | — | — | EP | claimed |
| WO-2004098572-A1 | BIPHASIC RELEASE OF GLIPIZIDE FROM MONOCOMPARTMENT OSMOTIC DOSAGE FORM | RANBAXY LABORATORIES LIMITED (US) | 2004-11-18 | — | — | WO | claimed |
| US-20040175428-A1 | Controlled release by extrusion of solid amorphous dispersions of drugs | PFIZER INC. | 2004-09-09 | — | — | US | claimed |
| US-6706283-B1 | INCREASING BIOAVAILABILITY OF SPARINGLY WATER SOLUBLE ACTIVE INGREDIENTS; CONTROLLED INFLUX OF WATER TO CORE USING NON-DISSOLVING, NONERODING COATING | PFIZER INC | 2004-03-16 | — | — | US | claimed |
| WO-2003092660-A1 | MONOCOMPARTMENT OSMOTIC CONTROLLED DRUG DELIVERY SYSTEM | RANBAXY LABORATORIES LIMITED (US) | 2003-11-13 | — | — | WO | claimed |
| US-6365185-B1 | ORAL TABLET FOR DELIVERING BENEFICIAL AGENT TO MAMMAL COMPRISING CORE COMPARTMENT HAVING BENEFICIAL AGENT SURROUNDED BY UNITARY SELF-DESTRUCTING SHELL COMPRISING PLURALITY OF DISINTEGRANT PARTICLES DISPERSED WITHIN SEMIPERMEABLE MATRIX | UNIVERSITY OF CINCINNATI | 2002-04-02 | — | — | US | claimed |
| EP-1027888-A2 | Osmotic system for delivery of solid amorphous dispersions of drugs | Pfizer Products Inc. (US) | 2000-08-16 | — | — | EP | claimed |
| US-5612059-A | CELLULOSE DERIVATIVE, DRUG DELIVERY | PFIZER INC. (US) | 1997-03-18 | — | — | US | claimed |
| EP-0326727-A1 | Sustained release implant and method for preparing same | INTERNATIONAL MINERALS AND CHEMICAL CORPORATION (US) | 1989-08-09 | — | — | EP | claimed |
| US-4761289-A | Sustained release implant and method for preparing same | INTERNATIONAL MINERALS & CHEMICAL CORP. (US) | 1988-08-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312606-A1 | MCL-1 INHIBITOR FORMULATIONS | MCL1, BAK1, BCL2L1 | ALDH1A1 650/4885TSHR 4494/4885HSD17B10 4391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.